Drug makers on why public funds not enough for vaccines
Managing IP is part of the Delinian Group, Delinian Limited, 4 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 00954730
Copyright © Delinian Limited and its affiliated companies 2023

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement
Cookies Settings

Drug makers on why public funds not enough for vaccines

Charlotte Kilpatrick
December 17, 2020
bad taste

Counsel from BMS and Oxford say COVID has shown why collaboration between public institutions and pharma companies is essential for drug development

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Take a Free Trial or Login

Topics

IP StrategyNewsInternationalPatents
kilpatrick-charlotte-300px.png
Charlotte Kilpatrick
Reporter Managing IP
Contact
Charlotte reports on patent-related issues. She often covers the European market, focusing on developments including FRAND, licensing and trade secrets. She is particularly interested in how new technologies affect IP challenges in the pharmaceutical industry.
more from across site and ros bottom lb

More from across our site

Magnet attracting people. Digital social marketing, Customer att
More begets more: how firms snatch up TTAB work
Firms explain how monitoring, referrals and relationships with foreign firms helped them get more work at the TTAB
Rani Mehta, December 01, 2023
Toft_Luke.jpg
How short in-house IP stint led to 'best of both worlds'
Luke Toft explains why he moved back to Fox Rothschild after working in-house at Sleep Number for five months
Rani Mehta, December 01, 2023
Generative AI.jpeg
This week on MIP: AI watershed, USPTO's SEP warning to EU
We provide a rundown of Managing IP’s news and analysis coverage from the week, and review what’s been happening elsewhere in IP
Rory O’Neill, December 01, 2023
AI create.jpeg
Chinese court allows copyright protection for AI-generated images
In a seminal ruling, the Beijing Internet Court said images generated by Stable Diffusion counted as original works
Sukanya Sarkar, November 30, 2023
John_Lanza.jpg
New Foley Hoag partner seeks more collab with pharma team
Boston-based John Lanza is hoping to work more with life sciences colleagues on the ‘exciting’ application of AI to drug discovery
Rani Mehta, November 30, 2023
India.jpg
Weekly take: Indian courts must scale up before tackling global SEP rates
The Delhi High Court has expressed its willingness to set global licensing terms in the Nokia-Oppo dispute, but it must deal with longstanding problems first
Sukanya Sarkar, November 30, 2023
Computer bug on laptop screen symbolizing threat of software bugs and elusive nature of zero day vulnerabilities in software security, critical bug in computer software
Law firms reveal bugbears after USPTO Patent Center switch
Some patent counsel are still encountering errors even though the USPTO has fully transitioned to the new system
Rani Mehta, November 29, 2023
EUbuildings
Proceed cautiously on SEPs, USPTO warns EU
A senior USPTO attorney spoke at a Nokia-sponsored event on the EU’s proposed SEP Regulation today, November 29
Rory O’Neill, November 29, 2023
Deepfake.jpg
Lawyers: India needs major legal reform to cope with deepfakes
IP counsel are ‘flooded’ with queries from clients worried about deepfakes, but the law has so far come up short
Sukanya Sarkar, November 29, 2023
Charlene.Azema-HR.jpg
Five minutes with … Charlene Azema, Knobbe Martens
Each week Managing IP speaks to a different IP practitioner about their life and career
Max Walters, November 28, 2023